Evidence map›Paper›PMID 27657042›Full record

ArticleInternational journal of molecular sciences2016

Effect of Thyrotropin on Osteopontin, Integrin α

Yumeng Yan, Fengwei Jiang, Yaxin Lai, Haoyu Wang, Aihua Liu, Chuyuan Wang, Yuanyuan Zhang, Weiping Teng, Zhongyan Shan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Actions of Thyroid Hormones on Thyroid Cancers.Frontiers in endocrinology · 2021
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yumeng YanDepartment of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning, China. cherylyanyumeng@hotmail.com.
Fengwei JiangDepartment of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning, China. winnterrain0923@tom.com.
Yaxin LaiDepartment of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning, China. laiyaxin811005@126.com.
Haoyu WangDepartment of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning, China. why_endocrinology@foxmail.com.
Aihua LiuDepartment of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning, China. liuaihuacmu@163.com.
Chuyuan WangDepartment of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning, China. chuyuan0215@163.com.
Yuanyuan ZhangDepartment of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning, China. yuan-anpo@126.com.
Weiping TengDepartment of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning, China. twp@vip.163.com.
Zhongyan ShanDepartment of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning, China. shanzhongyan@medmail.com.cn.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous epidemiological studies have shown that subclinical hypothyroidism (SCH) can impair endothelial function and cause dyslipidemia. Studies have evaluated the effects of thyroid stimulating hormone (TSH) on endothelial cells, but the mechanism underlying the proatherosclerotic effect of increased TSH levels remains unclear. In the present study, SCH rat models were established in thyroidectomized Wistar rats that were given ʟ-T₄ daily. The results showed that in vivo, the expression of osteopontin (OPN) vascular cell adhesion molecule (VCAM-1), and levels of integrin α

Indexed as

atherosclerosisosteopontinsubclinical hypothyroidismthyrotropin

Identifiers

PMID27657042
PMCPMC5037762
OpenAlexW2523081263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.